Sanoculis Achieves CE Mark for MINT® Glaucoma Treatment Technology in Europe

Sanoculis Ltd. Receives CE Mark for Innovative MINT® Technology

On April 17, 2025, Sanoculis Ltd., a leading company in ophthalmic medical device technology, announced that it successfully obtained the CE Mark for its groundbreaking MINT® (Minimally Invasive Nasal Trabeculostomy) product. This product is specifically designed to assist adult patients undergoing procedures for glaucoma, a condition affecting millions globally.

What is MINT®?

MINT® represents a state-of-the-art, stent-free technological platform that aims to revolutionize the treatment of glaucoma. Its unique semi-automatic trepanation technology operates with a tip diameter of just 0.14 mm, allowing for precise openings within the trabecular meshwork, which plays a crucial role in eye pressure regulation. This innovation seeks to enhance the standard of care by providing a less invasive yet effective treatment option, ultimately offering better outcomes for patients.

CEO and co-founder of Sanoculis, Nir Israeli, highlighted the significant impact of MINT® on the field of minimally invasive glaucoma surgery (MIGS). He stated, "MINT® signifies a major shift in glaucoma treatment, with the potential to enhance patient outcomes and elevate care standards." Clinical data emerging from a two-year prospective, single-arm study indicates that MINT® effectively lowers intraocular pressure (IOP) while simultaneously reducing the need for glaucoma medications, making it an attractive option for patients.

The Need for Innovative Treatments

Globally, glaucoma affects approximately 76 million individuals, a number projected to rise to 112 million by 2040. This condition is the second leading cause of irreversible blindness worldwide. Most glaucoma cases are chronic, and if not identified and treated promptly, they can lead to permanent vision loss. Early detection and effective treatment are critical in preventing visual impairment caused by optic nerve deterioration, which results in progressive loss of the visual field.

Current treatment paradigms primarily start with topical eye drops, which may subsequently be followed by laser therapy or minimally invasive surgeries (MIGS) before resorting to traditional surgical methods. MINT® aims to fill a critical gap in this sequence of treatment options, providing a less invasive method that addresses the underlying issues effectively.

The Future for Sanoculis

Following the CE Mark acquisition, Sanoculis plans a selective market launch of the MINT® technology within the year, further expanding its impact in the ophthalmic field. The company's commitment to developing innovative, stent-free technology platforms underscores its dedication to improving treatment standards and patient outcomes.

Sanoculis specializes in creating cutting-edge, minimally invasive solutions for glaucoma surgeries, including sclerectomy and trabeculotomy. Their goal is to transform the way glaucoma is managed through innovative methodologies that improve both the patient's experience and the results of their treatments.

With the launch of MINT®, Sanoculis not only advances its mission but also promises to reshape glaucoma treatment, paving the way for better healthcare solutions in this critical area of eye health. For partnerships and more information about the MINT® system, readers can visit the company’s official resources or reach out directly to their marketing team.

For further details, you can watch the related video here.